Induction of resistance to Aplidin® in a human ovarian cancer cell line related to MDR expression

Cancer Biology and Therapy

Volumn 4, Issue 12, 2005, Pages 1325-1330

  Tognon, Gianluca ^a   Bernasconi, Sergio ^a   Celli, Nicola ^b   Faircloth, Glynn T ^c   Cuevas, Carmen ^d   Jimeno, José ^d   Erba, Eugenio ^a,e   D'Incalci, Maurizio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Santa Maria Imbaro   (Italy)

^c PharmaMar USA Inc   (United States)

^d PHARMAMAR S A   (Spain)

^e Flow Cytometry Unit   (Italy)

Author keywords

Aplidin ; Flow cytometry; Marine natural compound; Pgp expression; Resistant cell line

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; COLCHICINE; CYCLOSPORIN A; DEHYDRODIDEMNIN B; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PACLITAXEL; TRABECTEDIN; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION;

EID: 31144462030     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.12.2157     Document Type: Article

References (28)

1. Urdiales JL, Morata P, Nunez De Castro I, Sanchez-Jimenez F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102:31-7.
2. Lobo C, Garcia-Pozo SG, Nunez de Castro I, Alonso FJ. Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res 1997; 17:333-6.
3. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 1998; 78:739-44.
4. Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol 1999; 44:312-8.
5. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, Vignati S, Codegoni A, Desiderio MA, Faircloth G, Jimeno J, D'Incalci M. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer 2002; 86:1510-7.
6. Erba E, Serafini M, Gaipa G, Tognon G, Marchini S, Celli N, Rotilio D, Broggini M, Jimeno J, Faircloth GT, Biondi A, D'Incalci M. Effect of Aplidin in acute lymphoblastic leukaemia cells. Br J Cancer 2003; 89:763-73.
7. Bresters D, Broekhuizen AJ, Kaaijk P, Faircloth GT, Jimeno J, Kaspers GJ. In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: A rational basis for clinical development. Leukemia 2003; 17:1338-43.
8. Faircloth G, Perez J, Fernandez JLSP, Avila J, Garcia M, Erba E, D'Incalci M, Canedo A, Garcia de Quesada T, Jimeno J. Marine depsipeptides with activity against solid tumour models [abstract]. Paris: Prooceedings 8th ECCO Congress, 1995:529.
9. Faircloth G, Rinehart K, Nunez de Castro I, Jimeno J. Dehydrodidemnin B (DDB) a new marine derived antitumour agent (MDA) with activity against experimental tumour models [abstract]. Ann Oncol 1996; 7:34.
10. Crampton SL, Adams EG, Kuentzel SL, Li LH, Badiner G, Bhuyan BK. Biochemical and cellular effects of didemnins A and B. Cancer Res 1984; 44:1796-801.
11. Sakai R, Rinehart KL, Kishore V, Kundu B, Faircloth G, Gloer JB, Carney JR, Namikoshi M, Sun F, Hughes Jr RG, Garcia Gravalos D, de Quesada TG, Wilson GR, Heid RM. Structure - activity relationships of the didemnins. J Med Chem 1996; 39:2819-34.
12. Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1alpha. J Biol Chem 1994; 269:15411-4.
13. Broggini M, Marchini S, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003; 17:52-9.
14. Marchini S, Chiorino G, Faircloth GT, D'Incalci M. Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines. J Biol Regul Homeost Agents 2002; 16:241-8.
15. Raymond E, Ady-Vago N, Baudin E, Ribrag V, Faivre SLF, Wright T, Lopez Lazaro L, Guzman C, Jimeno J, Ducreux M, Chevalier T, Armand JP. A phase I and pharmacokinetic study of aplidine (APL) given as a 24-hour continuous infusion every other week (q2w) in patients (pts) with solid tumor (ST) and lymphoma (NHL) [abstract]. Amsterdam: Proceedings 11th NCI-EORTC-AACR Symposium, 2000:86.
16. Armand JP, Ady-Vago N, Faivre S, Chieze S, Baudin E, Ribrag V, Lecot F, Iglesias L, Lopez-Lazaro L, Guzman C, Jimeno J, Ducreux M, Le Chevalier T, Raymond E. Phase I and pharmacokinetic study of aplidine (APL) given as a 24-hour continuous infusion every other week (q2w) in patients (pts) with solid tumor (ST) and lymphoma (NHL) [abstract]. San Francisco: Proceedings 37th ASCO Annual Meeting, 2001:20:120a.
17. Ciruelos Gil EM, Twelves C, Dominguez MJ, McKay H, Anthony A, Castellanos D, Bezares S, Ruiz A, Lopez-Lazaro L, Jimeno J, Celli N, Cotes-Funes H, Paz-Ares L. Phase I clinical and pharmacokinetic study of the marine compound aplidine (APL) administered as a 3 hour infusion every 2 weeks. Orlando: Proceedings 38th ASCO Annual Meeting, 2002:106a.
18. Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, Vignati S, Faircloth G, Jimeno J, D'Incalci M. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 2000; 82:1732-9.
19. Celli N, Mariani B, Di Carlo F, Zucchetti M, Lopez-Lazaro L, D'Incalci M, Rotilio D. Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection. J Pharm Biomed Anal 2004; 34:619-30.
20. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
21. Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. Peptide transport by the multidrug resistance pump. J Biol Chem 1992; 267:5731-4.
22. Sarkadi B, Muller M, Homolya L, Hollo Z, Seprodi J, Germann UA, Gottesman MM, Price EM, Boucher RC. Interaction of bioactive hydrophobic peptides with the human multidrug transporter. Faseb J 1994; 8:766-70.
23. Sharom FJ, Yu X, DiDiodato G, Chu JW. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. Biochem J 1996; 320(Pt 2):421-8.
24. Sharom FJ, DiDiodato G, Yu X, Ashbourne KJ. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem 1995; 270:10334-41.
25. Sharom FJ, Lu P, Liu R, Yu X. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: Peptide binding and effects on drug transport and accumulation. Biochem J 1998; 333(Pt3):621-30.
26. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005; 11:2320-6.
27. Danks MK, Yalowich JC, Beck WT. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 1987; 47:1297-301.
28. Losada A, Lopez-Oliva JM, Sanchez-Puelles JM, Garcia-Fernandez LF. Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin. Br J Cancer 2004; 91:1405-13.